Table 1 Demographic and clinical parameters in PAD patients (n = 262).
From: Trimethylamine-N-Oxide (TMAO) Predicts Cardiovascular Mortality in Peripheral Artery Disease
PAD (n = 262) | IC n = 147 | CLI n = 115 | p vs IC | |
|---|---|---|---|---|
Demographic and clinical data | ||||
Sex (male, %) | 87 | 88 | 85 | 0.442 |
Age (years) | 70 (11) | 68 (10) | 73 (11) | <0.001 |
Smokers (%) | ||||
Never | 20 | 12 | 29 | 0.004 |
Current | 32 | 35 | 29 | |
Former | 48 | 53 | 42 | |
Diabetes mellitus (%) | 53 | 36 | 74 | <0.001 |
Hypertension (%) | 74 | 72 | 77 | 0.331 |
Dyslipidemia (%) | 62 | 67 | 57 | 0.093 |
BMI (kg/m2) | 28 (5) | 28 (5) | 28 (6) | 0.830 |
ABI | 0.55 (0.19) | 0.62 (0.17) | 0.38 (0.13) | <0.001 |
Personal history (%) | ||||
COPD | 14 | 14 | 13 | 0.772 |
CKD | 39 | 24 | 58 | <0.001 |
AMI | 28 | 26 | 30 | 0.486 |
Cardiomyopathy | 25 | 14 | 38 | <0.001 |
Cerebral ischemia | 9 | 5 | 14 | 0.009 |
Treatment (%) | ||||
Anticoagulants | 13 | 8 | 20 | 0.005 |
Antiplatelets | 77 | 82 | 70 | 0.033 |
ACE inhibitors | 34 | 32 | 36 | 0.440 |
ARA-2 | 27 | 23 | 32 | 0.102 |
Calcium antagonists | 22 | 18 | 27 | 0.071 |
Vasodilators | 7 | 6 | 8 | 0.589 |
β-Blockers | 24 | 24 | 23 | 0.722 |
Statins | 65 | 69 | 59 | 0.084 |
Laboratory data | ||||
Total col (mg/mL) | 172 (46) | 187 (41) | 153 (47) | <0.001 |
LDL-C (mg/dL) | 110 (91) | 114 (83) | 104 (99) | 0.360 |
HDL-C (mg/dL) | 43 (16) | 49 (15) | 36 (13) | <0.001 |
Triglycerides (mg/dL) | 145 (81) | 151 (88) | 138 (70) | 0.194 |
hs-CRPa (mg/mL) | 5 (11) | 3 (4) | 10 (22) | <0.001 |
AST (U/L) | 21 (9) | 21 (9) | 20 (8) | 0.194 |
ALT (U/L) | 21 (14) | 22 (14) | 19 (13) | 0.081 |
GGT (U/L) | 54 (69) | 50 (61) | 60 (78) | 0.244 |
eGFR (mL/min/1.73 m2) | 73 (21) | 79 (19) | 66 (22) | <0.001 |
